Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myeloma
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000016265
- Lead Sponsor
- Sapporo Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Non-secretory multiple myeloma or plasma cell leukemia. HIV-, HBs-, or HCV-positive patients. Severe or uncontrolled hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension, infection, or psychiatric disorder. Patients with active and progressive malignancy. Women who are pregnant or in lactation. Those who are considered as inappropriate to register by attending physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate Incidence of adverse events
- Secondary Outcome Measures
Name Time Method